- Conditions
- Healthy
- Interventions
- BAF 312
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 1,234
matching trials from the live ClinicalTrials.gov search.
- Conditions
- T-cell NHL (PTCL or CTCL)
- Interventions
- KK2223
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 14
- States / cities
- Duarte, California • Orange, California • Stanford, California + 11 more
- Conditions
- Solid Tumors
- Interventions
- CX-904
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Nashville, Tennessee • Houston, Texas + 2 more
- Conditions
- Cancer
- Interventions
- GSK2636771
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- NNC0642-1895, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy Volunteer, Psoriasis
- Interventions
- ABBV-547, ABBV-547 Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more
- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 355, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more
- Conditions
- Phenylketonuria, Healthy
- Interventions
- SYNB1618, Placebo
- Drug
- Lead sponsor
- Synlogic
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
- Conditions
- HIV Infections
- Interventions
- VH4524184, Midazolam, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Ovarian Cancer
- Interventions
- TJ102
- Biological
- Lead sponsor
- Phrontline Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orlando, Florida • Lake Success, New York + 5 more
- Conditions
- Cancer, Oncology, Tumors, Advanced Malignancy, Advanced Solid Tumors, Oncology Patients
- Interventions
- AMG 208
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • St Louis, Missouri • Houston, Texas
- Conditions
- Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas, Ovarian Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer
- Interventions
- PCNA Inhibitor AOH1996
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Duarte, California • Long Beach, California
- Conditions
- Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma
- Interventions
- upifitamab rilsodotin
- Drug
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Advanced Solid Tumor
- Interventions
- APR-1051
- Drug
- Lead sponsor
- Aprea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- New Brunswick, New Jersey • Cleveland, Ohio • Houston, Texas + 3 more
- Conditions
- Solid Tumor, Adult
- Interventions
- IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + cemiplimab combination therapy
- Biological
- Lead sponsor
- Immune-Onc Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Beverly Hills, California • Lone Tree, Colorado + 20 more
- Conditions
- Solid Tumors, Metastatic Solid Tumors
- Interventions
- DS3610a
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- M1069
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Hackensack, New Jersey • Nashville, Tennessee
- Conditions
- Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer, Lung Cancer, Melanoma, Ovarian, NSCLC
- Interventions
- SI-B036
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 4 more
- Conditions
- HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
- Interventions
- NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Duarte, California • La Jolla, California • Denver, Colorado + 16 more
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- DB-1317
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Complement Mediated Diseases
- Interventions
- AMY-101
- Drug
- Lead sponsor
- Amyndas Pharmaceuticals S.A.
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Influenza
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Translational Oncology Research International
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
- Interventions
- upifitamab rilsodotin
- Drug
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma